Risk assessment of the fungicide Aviator Xpro EC 225 with the active substances bixafen and prothioconazole by Norwegian Scientific Committee for Food Safety
 [Skriv inn tekst] 
 
 
 
 
 
 
 
 
 
 
 
 
Opinion of the Panel on Plant Protection Products of the Norwegian 
Scientific Committee for Food Safety 
 
 
Date:  03.07.13  
Doc. no.: 13-204 
ISBN:  978-82-8259-098-3 
Risk assessment of the fungicide Aviator Xpro EC 
225 with the active substances bixafen and 
prothioconazole 
 Norwegian Scientific Committee for Food Safety (VKM) 13-204 
 
Table of Contents 
 
Table of Contents ..................................................................................................................... 1 
Contributors ............................................................................................................................. 3 
Summary ................................................................................................................................... 4 
Background ............................................................................................................................... 5 
Terms of reference ................................................................................................................... 5 
1 Background documentation ........................................................................................ 6 
2 Procedure ...................................................................................................................... 6 
2.1 Health risk assessment ......................................................................................................................... 6 
2.2 Environmental risk assessment ............................................................................................................ 7 
3 Summary by the Norwegian Food Safety Authority (hazard identification, 
hazard characterization and assessment of exposure) .......................................................... 8 
3.1 Identity and physical/chemical data ..................................................................................................... 9 
3.2 Mammalian toxicology ...................................................................................................................... 10 
3.3 Environmental fate and ecotoxicological effects ............................................................................... 15 
3.4 Dossier quality and completeness ...................................................................................................... 19 
4 Risk characterization ................................................................................................. 19 
4.1 Summary of human toxicity/inherent properties ................................................................................ 19 
4.2 Environmental fate assessment .......................................................................................................... 23 
4.3 Environmental risk characterization .................................................................................................. 25 
4.4 Quality of the submitted documentation ............................................................................................ 25 
5 Conclusion ................................................................................................................... 25 
5.1 Health ................................................................................................................................................. 25 
5.2 Environment ....................................................................................................................................... 26 
6 Documentation ............................................................................................................ 26 
 
  
2 
 
 Norwegian Scientific Committee for Food Safety (VKM) 13-204 
 
Contributors 
Persons working for VKM, either as appointed members of the Committee or as ad hoc 
experts, do this by virtue of their scientific expertise, not as representatives for their 
employers. The Civil Services Act instructions on legal competence apply for all work 
prepared by VKM. 
 
Assessed by 
VKMs Panel on Plant Protection Products: 
Line Emilie Sverdrup (Chair), Christine Bjørge, Ole Martin Eklo, Merete Grung, Torsten 
Källqvist, Ingeborg Klingen, Marit Låg, Erik Ropstad, Steinar Øvrebø.  
 
VKM Scientific coordinator  
Edgar Rivedal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 Norwegian Scientific Committee for Food Safety (VKM) 13-204 
 
Summary 
Aviator Xpro EC 225 is a new fungicide for use in cereals, containing the new active 
substance bixafen and the already approved active substance prothioconazole. 
Prothioconazole was assessed by the Norwegian Scientific Committee for Food Safety in 
2006, and is therefore not included in this report.  
VKM was requested by the Norwegian Food Safety Authority to consider the possible health 
risk for operators related to the properties of bixafen used in Aviator Xpro EC 225; in 
particular to evaluate the relevance of the effects of bixafen on liver and coagulation 
parameters observed in rats and mice, thyroid tumours and reproductive effects observed in 
rats, and the establishment of NOAELs and reference values. VKM was also asked to 
evaluate the fate and behaviour of bixafen in the environment, and the ecotoxicological 
effects and risks related to its use. The risk assessment was finalized in a meeting on May 24. 
2013 by VKM’s Scientific Panel on Plant Protection Products. 
 
VKM’s conclusions are as follows:  
Health 
VKM concluded that the liver effects reported in sub-chronic and chronic studies in rats, dogs 
and mice exposed to bixafen, as well as the effects on coagulating parameters, should be 
considered adverse and of relevance to humans. 
It is the opinion of VKM that the thyroid follicular cell tumours reported in female rats 
exposed to bixafen is not sufficient to suggest that bixafen has a tumour inducing potential.  
It is further the opinion of VKM that it cannot be excluded that the reduced pup weight during 
lactation in the two-generation study is mediated by bixafen via the milk, and that bixafen has 
a direct effect on the number of stillborn pups in the F1 and F2 generation.     
Finally, the pup developmental variants and anomalies reported in the teratogenicity study are 
considered treatment related, and not as secondary effects related to maternal toxicity. 
VKM proposes a NOAEL of 2.0 mg/kg bw/day based on a 2 year feeding study in rats. 
VKM support/propose: 
• ADI: 0.02 mg/kg bw/day 
• AOEL: 0.13 mg/kg bw/day 
• ARfD: 0.2 mg/kg bw/day   
Risk calculations show minimal risk if personal protective equipment is used. 
Environment 
Bixafen is shown to be persistent in soil. VKM considers the results from a field study on a 
German site and the Finnish PEC calculator to be relevant and concludes that repeated annual 
applications can cause accumulation in soil under Norwegian conditions. There is also a 
potential for groundwater contamination from leaching of the metabolite M44. 
VKM has concluded that the use of bixafen as an ingredient in Aviator Xpro EC 225 with the 
proposed application regime in Norway will represent a minimal risk for toxic effects to 
terrestrial organisms.   
The toxicity of bixafen to aquatic organisms is high, and minimal risk of effects in surface 
waters can be achieved only if risk mitigation measures with bufferzones of 10 m are applied. 
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Background 
VKM performs risk assessments in the context of pesticide registration cf. Regulation on 
Pesticides § 4. The Norwegian Food Safety Authority, National Registration Section, is 
responsible for reviewing and evaluating the documentation submitted by the pesticide 
notifier. The Norwegian Food Safety Authority takes the final regulatory action regarding 
registration or deregistration of pesticides based on VKMs risk assessment, along with a 
comparative assessment of risk and benefits, and the availability of alternatives (the principle 
of substitution).  
The Norwegian Food Safety Authority submitted a request on April 18, 2013 for VKM to 
perform a risk assessment on use of the pesticide Aviator Xpro EC 225 containing the new 
active substance bixafen and the already approved active substance prothioconazole. The 
application is for use as a fungicide in cereals. Prothioconazole was assessed by the 
Norwegian Scientific Committee for Food Safety in 2006, and is therefore not included in this 
report. The risk assessment was finalized in June, 2013. 
 
Terms of reference 
Aviator Xpro EC 225 is a new product containing the active substance bixafen and the 
already approved active substance prothioconazole. The application is for use as a fungicide 
in cereals. Prothioconazole was assessed by the Norwegian Scientific Committee for Food 
Safety in 2006, and is therefore not included in this report.  
In this regard, The Norwegian Food Safety Authority would like an assessment of the 
following: 
• The human health risk for operators related to the properties of bixafen used in 
Aviator Xpro EC 225. The Panel is in particular asked to look at the following:  
o Evaluation of the effects of bixafen on the liver and the perturbation of the 
coagulation parameters observed at low doses, and if these should be 
considered as adverse effects.  
o Evaluation of the arguments put forward by the notifier stating that the 
perturbation of the coagulation parameters observed in studies on rat and 
mouse was due to vitamin K deficiency in the diet. 
o The relevance for humans of tumors observed in thyroid in the rat study. 
o Evaluation of the reproductive effects of bixafen observed in rats, 
especially fetus mortality and changes in pup body weight and organ 
weight during lactation. 
o Evaluation of the effects of bixafen observed in the teratogenicity study on 
rabbits. 
o The establishment of NOAELs and reference values (ADI, AOEL and 
ARfD). 
• The fate and behaviour in the environment and the ecotoxicological effects and risks 
with regard to the properties of bixafen used in Aviator Xpro EC 225.  
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1 Background documentation 
VKM’s risk assessment is based on the Norwegian Food Safety Authority’s evaluation of the 
documentation submitted by the applicant. The Norwegian Food Safety Authority publishes 
both their evaluation of Aviator Xpro EC 225 and their final regulatory action on the 
registration of the pesticide product at their homepage www.Mattilsynet.no. 
2 Procedure 
The first three steps of the risk assessment (hazard identification, hazard characterization and 
assessment of exposure) are performed by the Norwegian Food Safety Authority and involve 
an assessment of the documentation submitted by the pesticide notifier. The resulting report 
on hazard identification, hazard characterization and assessment of exposure, from which the 
summary is included in the present document, is then reviewed by VKM. This review may 
result in some amendments in the original documents of both the summary and the full report 
issued by the Norwegian Food Safety Authority (2011). The fourth step (risk characterization) 
is based on the three first steps and is VKM’s conclusions or risk assessment.  
 
2.1 HEALTH RISK ASSESSMENT 
The assessment of health risk of pesticides is based on the adverse effects produced by the 
active substance and product in several experimental test systems including long term animal 
studies. On the basis of this, limits of exposure which represent no health risk are determined. 
The limits take account of the uncertainties of extrapolating data from animals to humans and 
are compared to the operator exposure and human exposure to possible residues in food.  
The UKPoem and the German model are used to estimate operator exposure. The models are 
based on a limited number of studies and are not validated. Thus, the models may not always 
be sufficiently representative for Norwegian conditions. The limitations of model estimates of 
exposure are taken into consideration when the calculated level of exposure is close to the 
threshold limit for acceptable operator exposure (Acceptable Operator Exposure Level; 
AOEL). VKM uses the 75 percentile of exposure assessment for both UK poem and German 
model. VKM has to base the assessment on the models whenever exposure data for the 
product is missing.  
VKM makes use of a higher safety factor when calculating AOEL and ADI in cases where the 
product contains critical active substances with serious adverse inherent properties (toxic to 
reproduction or carcinogenic). 
In order to describe the exceeding of maximum tolerated dose, VKM makes use of a scale. 
The scale is based on the ratio between the estimated exposure based on models or measured 
exposure in field studies and the Acceptable Operator Exposure Level (AOEL). In cases 
where the estimated exposure significantly exceeds AOEL, the use of the products may lead 
to increased risk for health effects.  
 
The following scale is used: 
Very high excess of AOEL more than 500% of the limit   
High excess of AOEL  300 – 500% of the limit  
Medium excess of AOEL 150-300% of the limit  
Moderate excess of AOEL  100-150% of the limit    
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The limit is not exceeded 
 
VKM may also consider co-formulants in the product when risk is to be determined. 
Consequently, if a product contains critical co-formulants it may be assessed to represent 
higher risk than what the inherent properties of active substances imply.   
 
 
2.2 ENVIRONMENTAL RISK ASSESSMENT 
The environmental risk assessment of pesticides involves predictions of exposure 
concentrations in various environmental compartments (e.g. soil and surface waters) that may 
occur after application of the pesticide. These predicted effect concentrations (PECs) are 
compared to exposure levels that are known to cause toxic effects to important groups of 
organisms representing the environmental compartments.  
The environmental fate and possible ecotoxicological effects of pesticides are investigated in 
several laboratory- and field experiments. In environmental risk assessments of pesticides, 
Predicted Environmental Concentrations (PECs) are estimated by use of different scenarios 
for different parts of the environment (terrestrial, aquatic). The first parameter estimated is 
usually the initial concentration (PIEC, Predicted Initial Environmental Concentration), e.g. 
the concentration just after application (usually spraying). PIEC in soil is calculated assuming 
a homogenous distribution of areal dose in the upper 5 cm soil layer. For surface water, the 
PIEC is based on deposition of pesticides from spray drift in a standard size water body. The 
calculations are performed with application of buffer zones between the sprayed area and the 
water body. 
The further exposure regime in different compartments is affected on the fate of the pesticide. 
The fate is dependent on processes such as photo degradation, hydrolysis, biodegradation and 
sorption to soil particles. These processes are studied in several standardised laboratory tests. 
In addition, field tests are used to study the dissipation of the pesticide in various agricultural 
soils. Based on the experimental fate studies, factors describing different fate processes may 
be derived and used in models that describe the fate of the pesticide in the soil as well as the 
transport to surface water and ground water. The concentrations of the pesticide in water are 
estimated by use of models with relevant scenarios based on EU’s FOCUS-scenarios. The 
models produce maximum PEC and average PEC calculated for specified periods after 
pesticide application. In the surface water scenarios PEC is also calculated for the sediment 
phase. 
Then the Toxicity Exposure Ratio (TER) is estimated for different groups of organisms. The 
TER is calculated as the ratio between the toxicity for the organism in question (expressed as 
LC50, EC50, NOEC etc., depending on organism and study type) and PEC or PIEC. Trigger 
values for TER, which express the acceptability of the risk for different organisms, have been 
defined by the EU. The risk is considered minimal when the TER does not exceed the trigger 
value.  
In the terrestrial environment, the risk for toxic effects on bees and non-target arthropods is 
assessed according to other criteria. Hazard quotients for oral- (HQO) and contact toxicity 
(HQC) are estimated for bees. HQO and HQC are ratios between the standardized area dose of 
the product (g v.s. /ha) and acute toxicity for the bee (LD50, µg active ingredient/bee). Field 
experiments and expert evaluation is triggered whenever the hazard quotient is above 50.  
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For the non-target arthropods, the estimated hazard quotient (HQ) is the ratio between the 
area dose of the product (g active ingredient/ha), which is multiplied with a factor for multiple 
applications (MAF, multiple application factor) when appropriate, and the acute toxicity for 
the organism (LR50, g active ingredient/ha). According to EU, whenever the ratio value 
exceeds 2, further investigations are triggered.  
VKM makes use of a scale in order to describe the risk of exposure for different organisms 
which live within and outside the spraying field. The scale is based on the ratio between the 
estimated exposure and the limit or the ratio between the TER and the TER trigger value 
designated each group of organism.  
The following risk scale is used:  
Very high risk  more than 500% of the limit   
High risk  300 – 500% of the limit  
Medium risk   150-300% of the limit  
Moderate risk  110-150% of the limit 
Minimal risk   the limit is not exceeded 
The estimates of exposure concentrations are based on maximal concentrations, which exist 
during or shortly after spraying. The group of organism assessed (for example birds or leaf 
dwelling non-target organisms) is not always present during the period of maximal 
concentration. In the final risk assessment, VKM therefore takes into consideration whether, 
or to which extent, the organism in question actually will be exposed. This may cause that the 
risk is assessed lower than indicated by the scale above.  
Additionally, uncertainties in the data base both with regard to establishments of limits and 
models of exposure concentrations are taken into consideration if relevant. This may also 
cause that the risk is assessed lower or higher than the risk scale. Any deviation from the risk 
scale is justified in this document.  
 
 
3 Summary by the Norwegian Food Safety Authority 
(hazard identification, hazard characterization and 
assessment of exposure) 
Aviator Xpro EC 225 is a new product containing two active substances bixafen and 
prothioconazole. Bixafen is a new active substance. The intended use is as fungicide in spring 
wheat, winter wheat, triticale, barley, rye and oats. 
Aviator Xpro EC 225 has effect against several plant diseases caused by fungi or oomycetes. 
Aviator Xpro EC 225 is a mixture of two active substances with different mode of action. 
Both active ingredients have curative and preventive effects. They are systemic and can be 
quickly translocated within the plant. The standardized area dose is set to 1.25 L per hectare. 
Aviator Xpro 225 should be applied in a volume of 100 to 300 L/ha of water with a broadcast 
sprayer using ground directed spraying. Maximal recommended application number is 2 per 
season with 14-21 days in between.  
The Norwegian Institute for Agricultural and Environmental Research recommend approval 
in spring wheat, winter wheat, triticale, barley, rye and oats. 
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3.1 IDENTITY AND PHYSICAL/CHEMICAL DATA 
Product name:  Aviator Xpro EC 225 
 
Active substances: Bixafen and prothioconazole 
 
Formulation:  Emulsion concentrate EC 
 
Concentration of  
active substance: Bixafen 75g/l, prothioconazole 150 g/l 
 
IUPAC-name  
(bixafen): N-(3′,4′-dichloro-5-fluorobiphenyl-2-yl)-3-(difluoromethyl)-1-     
methylpyrazole-4-carboxamide 
CAS number  
(bixafen):         581809-46-3 
 
Structural formula: 
 
 
Molecular weight:  414.21 g/mol   
 
Water solubility:     Low   0.00049 g/l (20 °C) 
 
Vapour pressure: Low   4.6 x 10-8 Pa (20°C) 
 
Henrys law const.: Low  3.89 x 10-5 Pa m3 mol-1 
 
log Pow:  High  3.3 (25 °C) 
 
pKa:   - 
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3.2 MAMMALIAN TOXICOLOGY  
3.2.1 BIXAFEN 
 
3.2.1.1 Toxicokinetics 
Absorption: Bixafen was rapidly absorbed after oral administration. Based on the recoveries 
in bile, urine and carcasses, approximately 86% and 83% of the administered dose were 
absorbed by male and female rats, respectively. At low doses, the female rats AUC were 
approximately twice as high as those for males. Saturation of the absorption processes was 
noted at high doses. 
Distribution: Maximum concentrations in the organs and tissues were observed between 1 
and 8 hours after dosing.  A rapid decline of the radioactivity concentrations in all organs and 
tissues was observed between 1 and 48 hours after administration. Residues levels in the 
organs and tissues were generally low with highest level in in the liver. There was no 
evidence of bioaccumulation in males or females. 
Metabolism: Bixafen-desmethyl, formed by desmethylation of the pyrazole ring was the 
most predominant metabolite identified. Hydroxylation of bixafen and bixafen-desmethyl 
occurred at different positions, especially in the fluoro-phenyl ring.  Hydroxy compounds 
were further conjugated with glucuronic acid. N-conjugation of bixafen-desmethyl with 
glucuronic acid was also found. Bixafen was also found to be conjugated with glutathione, 
and this was a major metabolic reaction in bile. Bixafen-desmethyl was also conjugated with 
glutathione. Cleavage occurs up to 4% of the administered dose. 
Excretion: Approximately 93-99% of the administered dose had been eliminated in urine and 
faeces 72 hour after dosing. For all treatments, the urinary excretion was low (<3%) but 
female rats excreted approximately twice the amount of the administered radioactivity in 
urine than males. Biliary excretion was approximately 83% in males and 56% in females at 48 
hours after dosing. 
 
3.2.1.2 Acute toxicity 
Acute toxicity of bixafen is low. No mortalities or clinical signs of toxicity were observed in 
the acute oral or dermal studies. Clinical signs of toxicity were observed at the maximum 
achievable concentration in the inhalation study and included bradypnoea, laboured breathing, 
piloerection, flaccid paralysis of hindlimbs and ungroomed coat. Gross necropsy revealed 
mild discolouration of the lungs. 
 
3.2.1.3 Genotoxicity 
A complete battery of in vitro and in vivo genotoxicity studies was conducted with bixafen. 
Based on these studies, bixafen is not genotoxic. 
 
3.2.1.4 Subchronic toxicity 
In the short-term studies on rats, a dose related increase in protrombine time, reduction in 
bilirubin levels, slight enzyme induction and increased liver weight were observed. 
Centrilobular hepatic hypertrophy and thyroid follicular cell hypertrophy was also dose 
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related. Increases in platelets, cholesterol and γ-glutamyl transferase activity were observed at 
the high dose level. 
In the short-term studies on mice one female was found dead at the high dose level. This was 
related to haemorrhage. Dose related reduction in albumin and elevated ALAT and ASAT 
activities and liver effects were also observed. Focal/multifocal squamous cell hyperplasia in 
the stomach was observed at high dose level.  
In the short-term studies in the dog, increased liver weight and enlarged centrilobular 
hepatocytes with vacuolated cytoplasm were observed. Haematological changes indicating 
anaemia were noted at the high dose level. 
 
3.2.1.5 Chronic toxicity and carcinogenicity 
In the initial 2-year chronic toxicity and carcinogenicity study, significant mortality and signs 
of haemorrhage were observed early in the study. The analysis of the diet showed levels of 
vitamin K < 0.3 mg/kg. The haemorrhagic syndrome was attributed to the lack of vitamin K 
in the diet. All males were therefore terminated without necropsy.  The female rats remained 
in the study, but the diet was supplemented with 15.7 ppm vitamin K. At the high dose, two 
females died and this was attributed to haemorrhagic syndrome possibly caused by the low 
vitamin K3 content in the diet at the beginning of the study. Total bilirubin levels were 
reduced at all dose levels. A dose-related increase in cholesterol levels was also observed. 
Histopathological findings in the liver included centrilobular to panlobular hepatocellular 
hypertrophy and an increased incidence and/or severity of hepatocellular brown pigments and 
multinucleated hepatocytes. In the thyroid, there were increased incidences and/or severity of 
follicular cell hypertrophy, colloid alteration, brown pigments in follicular cells, follicular cell 
hyperplasia and an increase in the incidence of follicular cell tumours (adenoma & carcinoma 
incidences combined). 
In the complementary male rat chronic toxicity and carcinogenicity study (supplemented with 
8.2-10.6 ppm vitamin K), prothrombin times were significantly decreased. Dose-related 
reductions in total bilirubin were evident at all dose levels throughout the study. The 
cholesterol levels were also increased. The microscopic findings in the liver included 
increased incidences of centrilobular to panlobular hepatocellular hypertrophy, hepatocellular 
brown pigments, eosinophilic hepatocellular alterations and hepatic cystic degeneration.  In 
the thyroid, there were increased incidences of follicular cell hypertrophy, colloid alteration, 
brown pigments in follicular cells and follicular cell hyperplasia.  There was no evidence of 
any increase in the incidence of thyroid tumours.  
In the carcinogenicity mice study, increased mortality in males occurred at the high dose level 
during the first twenty weeks of the study. The analysis of the diet showed levels of vitamin K 
< 0.3 mg/kg. The haemorrhagic syndrome was attributed to the lack of vitamin K in the diet. 
The diet was then supplemented with 15.7 ppm vitamin K. Several changes to the 
haematological parameters were observed. Microscopic findings in the liver included 
increased incidence of centrilobular hepatocellular hypertrophy and vacuolation in both sexes.  
In addition, male livers had increased incidences of hepatocellular brown pigments, single cell 
degeneration necrosis, multinucleated hepatocytes and mononuclear infiltrate.  In the thyroid, 
there were increased incidences of follicular cell hyperplasia in both sexes. There was no 
evidence on any compound induced tumours in either sex. 
In the chronic/carcinogenicity studies in rat and mice increased mortality was observed in 
males. This was attributed a haemorrhagic syndrome occurring early in the study period. The 
notifier analysed the diet and found levels of vitamin K < 0.3 mg/kg. The notifier conducted 
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studies where diet was supplemented with vitamin K. These studies showed that bixafen did 
not result in any significant changes to blood coagulation parameters (see 5.1.10 
Mechanistic/supporting studies).The notifier then attributed the haemorrhagic syndrome 
observed in male rats and male mice in short-term and chronic studies to the lack of vitamin 
K in the diet.  
The notifier argued further that the occurrence of haemorrhagic syndrome and the increased 
mortality in males, but not in the females, were due to a combination of vitamin K deficiency 
and enzyme induction seen in males. According to the notifer a literature search provided 
evidence for a synergistic effect of diets deficient in vitamin K and presence of liver enzyme 
induction, occurring preferentially in male rats, when exposed to a wide variety of chemical 
compounds that induce liver metabolising enzymes, when there is low vitamin K in the diet.  
The chemicals that cause this synergistic response have in common induction of cytochrome 
P450 2B enzymes. It is hypothesised that induction of CYP450 2B and/or CYP450 3A4 
isoenzymes (i.e. those induced by PB) could result in reduction in one or more coagulation 
factors normally activated by the vitamin K cycle. 
The EU rapporteur member state (RMS, UK) concluded that while some information is 
supportive of the argumentation of the notifier, it is possible that bixafen has some inherent 
ability to impair blood coagulation in animals on a diet containing normally adequate levels of 
vitamin K. The RMS supported this conclusion by the following:  
• The quantitative data on vitamin K content of the diets are not available for most of 
the studies 
• The supplementation level of 16 ppm vitamin K is in excess of the minimum 
recommended level for the vitamin K content of rodent diets (about 1 mg/kg in the 
diet) 
• It is not clear what levels of vitamin K are appropriate for the testing and identification 
of a compound with anticoagulant or suspected anticoagulant properties in rodents 
• The magnitude of enzyme induction is not particularly great. 
 
EFSA has also concluded that the haemorrhagic effect observed at high doses in rats and mice 
does show that this is an intrinsic property of bixafen that may be masked by an excess of 
vitamin K in the diet.  
 
3.2.1.6 Reproductive toxicology and teratogenesis 
In the range finding one-generation rat study, there were treatment-related reductions on 
maternal body weight and body weight gain, some evidence of increased APTT times in 
males, increased liver and thyroid weights and reduced thymus weights.  During lactation, 
pup weights were reduced (birth weight was not affected) and changes in organ weights were 
observed.   
In the rat two-generation study, there were treatment-related reductions on maternal body 
weight and body weight gain, and parental organ weight changes (e.g. increased liver, kidney 
and spleen weight and reduced thymus weight). Hepatic hypertrophy (centrilobular and/or 
diffuse) was observed, this was associated with a decrease in vacuolisation.  F1 and F2 pup 
weights were reduced during the lactation periods, and the reductions in F1 pups persisted 
into adulthood. It is unclear whether the organ weight changes observed in F2 pups were 
treatment related or secondary to reductions in pup weight. Since birth weight was unaffected 
by treatment and the reductions in pup weight was seen already from lactation day 4 (in the 
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range-finding study), this effect might be caused by either the presence of test material in the 
dam’s milk, a change in the amount of milk produced by the dams or a change in the 
nutritional status of the milk. It cannot be excluded that the reduced pup weight during the 
lactation period is cause by the presence of the test material in the dam’s milk.  
The numbers of litters with stillborn pups were increased in the F1 and F2 generations when 
compared to concurrent controls, and were also slightly outside the historical control data for 
the laboratory. During the assessment in the EU this finding was regarded as inconsistent and 
insignificant, with minimal impact on overall numbers in the next generation, and the 
reproductive NOAEL was set at 2500 ppm. However, based on the increased number of 
stillborn at the highest dose level (2500 ppm), a NOAEL at 400 ppm should be considered. 
It should be noted that the Purina diet used in both reproduction studies contained 1.3 ppm 
vitamin K (as menadione). There was some evidence of an effect on coagulation parameters 
in the range finding study, but coagulation parameters were not evaluated in the main 
multigenerational study. 
In the rat developmental study, maternal body weight loss, reduced foetal weight and delayed 
skeletal development were observed.  In the rabbit developmental study, the maternal effects 
included marked mortality (abortions/failure to maintain pregnancy and sacrificed for humane 
reasons), clinical signs, body weight loss and reductions in body weight gain, increased liver 
weight, liver (white foci and prominent lobulation) and urinary bladders findings 
(enlarged/purulent contents). The rabbit foetal findings included an increase in the number of 
runts, reduced foetal weight and visceral and skeletal findings.  Adopting a precautionary 
approach, the increased percentage of litters with short innominate arteries and a dose related 
increase in the percentage of foetuses and litters with extra sternebral ossification site(s) at the 
mid and top dose levels are regarded as treatment related, because they are outside the 
historical control range.  
 
3.2.1.7 Neurotoxicity 
Not relevant.  
 
3.2.1.8 Mechanistic/supporting studies  
Male rats administered bixafen in diet (containing <0.3 ppm vitamin K3) exhibited a 
haemorrhagic syndrome (increased PT and APTT values) and a high rate of mortality. The 
addition of 16 ppm vitamin K to the diet significantly lowered these values after two weeks. 
The test material induced slight increases in serum TSH. A slight reduction of T3 and T4 was 
also seen. There was an increase in BROD activity. A slight increase was also observed in 
mean UDPGT activity. 
 
3.2.1.9 Humane data 
No data reported. 
 
3.2.1.10 Reference values  
ADI: Based on the NOAEL of 2.0 mg/kg bw/day determined for male rats and an assessment 
factor of 100, an ADI of 0.02 mg/kg bw/day can be proposed for bixafen. 
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AOEL: Based on the NOAEL of 12.9 mg/kg bw/day determined for the 90-day rat study an 
assessment factor of 100, a short-term systemic AOEL of 0.13 mg/kg bw/day can be proposed 
for bixafen. 
ARfD: Based on the NOAEL of 20.0 mg/kg bw/day determined for the rat development study 
an assessment factor of 100, an ARfD of 0.20 mg/kg bw/day can be proposed for bixafen. 
 
3.2.1.11 Metabolites  
Cereals is not a re-entry culture, therefore there is no risk of workers being exposed to plant 
metabolites. The exposure of crop inspectors to these metabolites is considered to be minimal, 
since the metabolites were found only in very low amounts in a 3N rotational crop study. 
 
3.2.1.12 Co-formulants 
One co-formulant is harmful if swallowed and its content in Aviator Xpro EC 225 is above 
the classification limit. 
 
3.2.2 AVIATOR XPRO EC 225 
3.2.2.1 Acute toxicity 
The studies conducted with Aviator Xpro EC 225 showed low toxicity by the oral and dermal 
rout of exposure. The product was not found irritating to the skin, nor found to be a dermal 
sensitizer. However, the product was found to be irritating to the eyes, and should be 
classified as eye irritating in category 2 (H319: Causes serious eye irritation) according to the 
CLP criteria. 
 
3.2.2.2 Classification and labelling  
Aviator Xpro EC 225 should be classified as an eye irritant in category 2 (H319: Causes 
serious eye irritation), according to the CLP criteria. 
3.2.2.3 Dermal absorption  
No dermal absorption study has been conducted with the product Aviator Xpro EC 225. 
Therefore, EFSA’s default values for dermal absorption (25% for the concentrated product 
and 75% for the spray dilution) have been used in the exposure calculations. 
3.2.2.4 Operator, worker and bystander exposure 
The AOEL for bixafen was exceeded in the UK Poem and in the German model without PPE 
(personal protective equipment). However, the estimated exposure was below the AOEL for 
bixafen when PPE was applied during mixing/loading and application. No re-entry activities 
are envisaged for the intended use, and the exposure estimates show no risk for bystanders. 
The combined level of exposure to the respective active substances (bixafen and 
prothioconazole) is acceptable for operators using field crop sprayers when personal 
protective equipment is worn. 
 
3.2.3 RESIDUES IN FOOD OR FEED 
The active substance prothioconazole and the product Proline EC 250 were evaluated by the 
Norwegian Scientific Committee for Food Safety in 2006. 
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Bixafen is a new active substance and Bayer CropScience AG has applied for approval in EU. 
The RMS (the United Kingdom) checked the completeness of the dossier and provided its 
initial evaluation of the dossier on bixafen in the Draft Assessment Report (DAR), which was 
received by the EFSA on 19 July 2011.  
The European Commission (see Draft review report for the active substance bixafen finalised 
in the Standing Committee on the Food Chain and Animal Health at its meeting on 15 March 
2013) supported the approval of the active substance bixafen. The EU concluded that it is 
appropriate to approve bixafen; however, it is necessary to include certain conditions and 
restrictions. Member States shall pay particular attention to the residues of bixafen and of its 
metabolites in rotational crops. 
 
3.3 ENVIRONMENTAL FATE AND ECOTOXICOLOGICAL EFFECTS 
3.3.1 ENVIRONMENTAL FATE AND BEHAVIOUR 
3.3.1.1 Degradation in soil 
Bixafen is very persistent under standard aerobic laboratory conditions with up to 91 % 
unchanged bixafen left at the end of the study and with a half-life of > 1 year. The only 
metabolite identified was BYF 00587-desmethyl-pyrazole-4-carboxylic acid (M44) which 
ranged from 0.4 to 2.9 % of Applied Radioactivity (AR). Bound residues summed up to 11.2 
% of AR within 120 days and CO2 to < 1.6 % of AR. The anaerobic degradation rate is low 
with DT50 > 1 year and no significant mineralization. Bound residue amounted to about 10 % 
AR. Photolysis cannot be regarded as an important route of degradation for bixafen in soil. 
Field dissipation studies indicate that the dissipation of bixafen is low in four Northern 
European soils, including a soil from a site in Sweden. The Hockey Stick model described the 
dissipation best, resulting in DT50s between 316 and 1235 days and a geometric mean of 537 
days. For modelling the field DT50 SFO values were normalised to 197 - 340 days with a 
geometric mean of 249 days. A 6 year long soil accumulation study has been performed 
giving results that indicate a continued accumulation during the trial with no clear plateau 
being reached. The geometric mean DT50 of metabolite M44 was 25.4 days. 
 
Aerobic degradation of the metabolite M44 has been investigated by using data from three of 
four soils in the degradation studies on bixafen. Half-lives were estimated to be between 11 
and 55 days (geometric mean of 25.4 days). 
 
3.3.1.2 Sorption/mobility 
The sorption of bixafen in 5 different soils can be classified as very high with Kf: 41-103 
(average 78) and Koc: 3477-4974 (average 3869). Average 1/n is 0,8766.  
 
3.3.1.3 Degradation in water 
Bixafen can be regarded as hydrolytically stabile. Photolysis is not an important degradation 
pathway for bixafen in water. According to the OECD criteria for ready biodegradability, 
Bixafen is not readily biodegradable. In a water/sediment study bixafen dissipated rather 
quickly from the water phase to the sediments with a half-life of about 25-27 days (SFO). The 
degradation for the whole system can be classified as low with DT50 > 1000 days (system 
values, SFO), geometric mean > 1000 days. DT90 > 1000 days. 
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3.3.1.4 Fate in air 
Bixafen is not likely to volatilise significantly. A theoretical calculation of the potential for 
photo-oxidation of bixafen in the atmosphere has been submitted indicating a first order DT50 
of 0.87 days. The ‘long-term’ half-life and chemical life time in the troposphere was 
estimated to be 1.31 days and 1.89 days, respectively.  
   
3.3.2 ENVIRONMENTAL  EXPOSURE 
3.3.2.1 Soil 
PECsoil, including PECplateau/accumulation has been estimated by Mattilsynet using the 
Finnish PEC calculator. PiEC (Predicted initial Environmental Concentration, immediately 
after the second application) was calculated to be 0.125 mg/kg and the maximum PEC 
(directly after application) after approximately 20 years of continuous use was 0.90 mg/kg 
when using worst case un-normalised field DT50. A clear plateau was not reached during the 
period the model runs.  
 
3.3.2.2 Groundwater: 
Bixafen is not likely to leach to groundwater at concentrations > 0.1 µg/L with the tested 
parameters. All nine EU scenarios gave 80th percentile PECgw values of <0,0001 µg/L even 
when using worst case input parameters in the modelling. 
 
Metabolite M44 has been seen to leach to groundwater above the limit of 0.1 µg/L in all nine 
FOCUS scenarios. An application of 2x125 g bixafen/ha was used in the modelling but it is 
not believed that a somewhat lower application rate would change the conclusion of the 
groundwater assessment much.  
 
3.3.2.3 Surface water and sediment: 
Modelling with the EU surface water scenarios has been performed by the applicant and 
presented in the DAR, but this modelling was performed with a somewhat higher application 
rate (125 g a.s./ha) than what is relevant for Norway resulting in a worst case Step 3 PECsw 
of 0.800 µg a.s./L. Highest PECsed from Step 3 modelling was 21.4 µg a.s./kg dw sediment 
but an accumulation modelling performed by RMS UK resulted in an accumulated PEC of 
95.7 µg/kg sediment. 
 
Highest PECsw from the step 3 modelling performed with the most relevant application rate 
of 1x 94 g a.s./ha was 0.6 µg/L and highest PECsed was 5.02 µg/kg (2x94 g a.s./ha). Not all 
surface water scenarios were run with the most relevant application rate for Norway. Spray 
drift appeared to be the major contributing factor for most scenarios except for one, where run 
off was more significant. 
 
A FOCUS step 4 modelling (using SWAN v 1.1.4), based on the results of the step 3 
modelling and applying a 5 meter spray buffer zone, resulted in a maximum PECsw of 0.57 
µg/L. 
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3.3.3 EFFECTS ON TERRESTRIAL ORGANISMS 
Where there are indications that the plant protection product is more toxic than what can be 
explained by the content of the active substances (or studies are only conducted with the 
product), or identified metabolites are more toxic than the active substances, these 
calculations are included in the summary below. If this is not the case, these values and 
calculations are omitted. 
 
3.3.3.1 Mammals 
Bixafen has low acute toxicity (LD50: >2000 mg/kg bw/d) to mammals. TERacute for the 
indicator species small herbivorous mammal and insectivorous mammal in cereals are 
estimated as 90 and 2419, respectively. These values do not exceed the trigger (<10). NOEC 
from reproductive study: 33.3 mg/kg bw/d. 
TERchronic is estimated to be 115 and 4.7 for insectivorous mammal and small herbivorous 
mammal, respectively. The first tier risk assessment for the small herbivorous mammal has 
been refined using the EFSA (2009) birds and mammals guidance document, resulting in a 
TERchronic of 16. This value does not exceed the trigger (<5). 
 
3.3.3.2 Birds 
Bixafen has low acute toxicity (LD50: >2000 mg/kg bw/d) to birds. TERacute for the indicator 
species in cereals (large herbivorous and insectivorous birds) is estimated as >284. This value 
does not exceed the trigger (<10).  NOEC for reproduction: 30 mg/kg bw/d. TERchronic is 
estimated to be 12.9 and 10.6 for large herbivorous bird and insectivorous bird, respectively. 
These values do not exceed the trigger (<5).   
  
3.3.3.3 Bees 
Bixafen has low contact (LD50: >121 µg a.s./bee) and oral (LD50: >100 µg a.s./bee) toxicity 
to bees. 
Hazard quotients for contact (Qhc) and oral exposure (Qho) are estimated to be 0.9 and 0.8, 
respectively. None of the hazard quotients exceed the trigger value (>50).  
 
3.3.3.4 Non-target arthropods 
Extended lab studies did not show effects above the trigger effect level of 50 % at relevant 
application rates.  
 
3.3.3.5 Earthworms 
Bixafen has low acute toxicity (LC50: 500 mg a.s./kg d.wt. soil) to earthworms. TERacute is 
estimated to be 556. This value does not exceed the trigger (<10).  The NOEC for bixafen is 
20.8 mg a.s./kg d.w. soil. TERchronic is estimated to be 23. This value does not exceed the 
trigger (<5). 
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3.3.3.6 Other soil macro organisms 
Since the soil DT90 for bixafen is >365 days, the toxicity of Aviator Xpro EC 225 has been 
tested on the springtail F. candida. The NOECreproduction is 52 mg product/kg d.wt. soil and the 
TER is estimated to be 32. This value does not exceed the trigger (<5). 
 
3.3.3.7 Litter degradation 
When DT90f is > 365 days, testing on organic matter breakdown is triggered. Based on the 
DT90f of bixafen (>1000 days), a product containing bixafen as the active substance has been 
tested on litter degradation. The results of this study show negligible effects on organic matter 
breakdown. 
 
3.3.4 EFFECTS ON AQUATIC ORGANISMS 
Where there are indications that the plant protection product is more toxic than what can be 
explained by the content of the active substances (or studies are only conducted with the 
product), or identified metabolites are more toxic than the active substances, these 
calculations are included in the summary below. If this is not the case, these values and 
calculations are omitted. The TER calculations below are based on maximum PEC-values 
from FOCUS surface water modelling and the lowest acute (LC50 or EC50) or chronic 
(NOEC) values for the different organism groups and substances. All calculations are based 
on an application rate of 9.4 g bixafen/daa, which is the applied application rate in Norway. A 
tiered approach is applied. Step 2 is calculated for all tested substances, and if the TER fails 
the triggers, higher steps are calculated. The EU triggers for TERacute and TERlong-term are 
>100 and >10, respectively. 
 
 
 
3.3.4.1 Fish 
Bixafen shows very high to extremely high acute toxicity (96h LC50: 95-105 µg a.s./L) and 
very high chronic toxicity (33 d NOEC: 4.6 µg a.s./L). Aviator Xpro EC 225 is acutely toxic 
to rainbow trout (96h LC50: 1550 µg/L). 
All acute TER calculations for bixafen pass the EU trigger based on Step 3 FOCUS surface 
water scenarios. Bixafen fail the EU trigger for long-term TER for Step 3, and need further 
refinement. Based on Step 4 calculations for other products/application rates, the risk is 
assumed to be acceptable with a 10 meter buffer zone. 
 
3.3.4.2 Invertebrates 
Bixafen is acutely toxic (48h EC50: 1200 µg a.s./L) and shows moderate chronic toxicity 
(EC50: 125 µg a.s./L) to daphnids. Aviator Xpro EC 225 is acutely toxic to daphnids (48h 
EC50: 3000 µg/L). 
All TER calculations (both acute and long-term) for bixafen pass the EU trigger based on 
Step 2 FOCUS surface water scenarios. 
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3.3.4.3 Sediment dwelling organisms 
Bixafen shows low to medium chronic toxicity to Chironomus riparius larvae (28 d NOEC: 
16 µg a.s./L (spiked water) and 20 000 µg/kg (spiked sediment)). 
All TER calculations for bixafen (both spiked water and spiked sediment) pass the EU trigger 
based on Step 2 FOCUS surface water scenarios. Even TER based on a calculation of PECacc 
after 20 years of use of bixafen pass the trigger.  
 
3.3.4.4 Aquatic plants 
No information. 
 
3.3.4.5 Algae 
Bixafen shows extremely high toxicity to green algae (72 h EC50: 60-97 µg a.s./L). Aviator 
Xpro EC 225 is acutely toxic to green algae (72h EC50: 1520 µg/L). 
All TER calculations for bixafen pass the EU trigger based on Step 2 FOCUS surface water 
scenarios. 
 
3.3.4.6 Microorganisms 
No information. 
  
3.3.4.7 Microcosm/Mesocosm studies 
No information. 
 
3.3.5 BIOCONCENTRATION 
Bixafen shows a high potential for bioconcentration (BCF: 695) but a rapid depuration 
(CT50: 1.3 days). 
 
3.4 DOSSIER QUALITY AND COMPLETENESS 
The dossier is complete and is adequate as a basis for an evaluation of the active substance, 
metabolites and product. 
 
4 Risk characterization 
4.1 SUMMARY OF HUMAN TOXICITY/INHERENT PROPERTIES  
In the terms of reference VKM was requested to consider the possible health risk for 
operators related to the properties of the active substance bixafen used in Aviator Xpro EC 
225; in particular the relevance of the observed effects of bixafen on liver and coagulation 
parameters in rats and mice, the thyroid tumours and reproductive effects observed in rats, 
and the establishment of NOAELs and reference values (ADI, AOEL and ARfD).  
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4.1.1 THE EFFECTS SEEN IN LIVER, AND THE PERTURBATION OF COAGULATION 
PARAMETERS   
Liver: VKM discussed the seriousness of the effects and concluded that the liver effects 
reported in sub-chronic and chronic studies in rats, dogs and mice should be considered as an 
adverse effect and relevant for humans. The effects included increased liver weight and 
centrilobular and panlobular hepatic hypertrophy in rats, mice and dogs, and an increased 
incidence of hepatocellular necrotic foci and single cell necrosis in liver in mice. The 
NOAELs for liver effects were 2.8 mg/kg bw/day (2-year study rat), 6.7 mg/kg bw/day (18-
month study mice) and 10 mg/kg bw/day (1-year study dog). The NOAEL value from the 2-
year rat study is used for deriving the ADI. 
 
Perturbation of the coagulation parameters: VKM discussed the seriousness of the effects 
and concluded that the adverse effects on coagulating parameters should be considered as an 
adverse effect and of relevance for humans. Effects on coagulation parameters were reported 
in sub-chronic studies and included an increase in platelet counts in rats and dogs, and longer 
prothrombine time in rats. In the 28-day mouse study, one male was found dead in the high 
dose group on day 7, and all remaining males and three females were sacrificed on study day 
8-14. One contributing factor to the death and severe conditions of the mice was internal 
bleeding. In a chronic study in mice, increase in platelet counts and decrease in haemoglobin 
and haematocrit were reported. Furthermore, in chronic studies in rats and mice, mortality 
was reported, and the deaths were attributed to a haemorrhagic syndrome. In the rat study, the 
pattern of mortality in male rats indicated a dose-and time depended relationship. The deaths 
were considered attributed to lack of Vitamin K in the diet. However, no deaths were reported 
in the unexposed group. The Vitamin K level in the diet was < 0.3 mg/kg while the 
recommended level is 1 mg/kg. The mortality in the mouse study was only reported in the 
high dose group, and was not considered related to low levels of Vitamin K in the diet. 
 
4.1.2 COAGULATION PARAMETERS AND VITAMIN K DEFICIENCY IN THE DIET 
Vitamin K in the diet was only measured in the 2-year rat study on bixafen. The analysis 
showed levels of vitamin K < 0.3 mg/kg. The haemorrhagic syndrome was by the notifier 
considered attributed to lack of vitamin K in the diet. However, no effects on coagulating 
parameters were reported in the unexposed control group receiving the same diet. Males were 
therefore prematurely sacrificed at approximately 25 weeks (117 mg/kg bw/day dose group) 
and 35 weeks (all remaining male rats). The female rats remained in the study, but the diet 
was supplemented with very high levels of vitamin K (15.7 ppm). For male rats, a new 2-year 
study was performed with very high vitamin K supplementation in the diet (8.2 to 10.6 ppm). 
No deaths were reported in this study. The level of 8.2 to 15.7 ppm vitamin K is in excess of 
the recommended level for vitamin K content in rodent diets, about 1 mg/kg .  
It is not clear what levels of vitamin K in the diet are appropriate when testing a compound 
with anticoagulant properties in rodents. In the experiment with low vitamin K content in the 
diet, the animals in the unexposed control group showed no symptoms related to coagulation, 
while exposed animals in the high dose group suffered from haemorrhage and death.  VKM 
concludes that the observed perturbations of the coagulating parameters are not likely to be 
explained by vitamin K deficiency in the diet. Experiments with very high concentrations of 
vitamin K in the diet should be interpreted with care in the evaluation of the toxic effects of 
suspected anticoagulants. It cannot be excluded that high doses of vitamin K may mask 
intrinsic effects of the test substance. Therefore, the adverse effects on coagulating parameters 
should be considered an adverse effect of bixafen. 
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4.1.3 RELEVANCE OF THE THYROID TUMOURS IN RAT STUDY  
In female rats, an increase in thyroid follicular cell tumour incidence (combined adenoma & 
carcinoma) was reported.  However, the increase was not significant and not dose-dependent. 
In male rats, no increase in thyroid follicular cell tumours was observed. Also in chronic 
studies in male and female mice, no thyroid follicular tumours were reported.  
Since the induction of thyroid tumours was only reported in female rats, and the number was 
not significant and not dose-related, the data is not sufficient to suggest that bixafen has a 
tumour inducing potential. 
 
4.1.4 REPRODUCTIVE EFFECTS IN RAT STUDY: FOETAL MORTALITY AND REDUCED BODY 
AND ORGAN WEIGHTS DURING LACTATION  
In the two-generation study, F1 and F2 pup body weight was significantly reduced during 
lactation in the high dose group; in F1 pups starting on lactation day 7, and in F2 pups on 
lactation day 14. In the one-generation study in rats, high dose male and female pup body 
weight was also reduced during lactation; starting on day 4 with more pronounced declines 
throughout lactation. The pup body weight was not affected at time of birth. Since reductions 
in pup weight was seen on lactation day 4 in the dose ranging study, it is unlikely that this is 
caused by pup consumption of solid food. Therefore, it cannot be excluded that the reduced 
pup weight during lactation is mediated by the presence of test material in the dam’s milk 
(Log Pow 3.3) or a change in suckling behaviour (the amount of milk produced by the dams 
or the natural status of the milk).  Furthermore, bixafen is shown to be transferred to milk in a 
feeding study with dairy cows. 
In the one-and two-generation studies, a significant reduction in relative organ weights (brain 
and spleen) were reported in male and female pups in the high dose group. This effect should 
be considered treatment related. 
In the two-generation study, the number of stillborn F1 pups, the number of F1 litters with 
stillborn pups and the number of F2 litters with stillborn pups were increased in the high dose 
group when compared to concurrent controls, and were slightly outside the historical control 
data for the laboratory. However, there was no dose response between the F2 low dose and 
high dose groups. In the one-generation study no increase in stillbirths was observed at a 
higher dose-level than in the two-generation study. VKM is of the opinion that it cannot be 
excluded that exposure to bixafen has a direct effect on the number of stillborn pups in the F1 
and F2 generation.   
 
NOAELS from the two-generation study: 
NOAEL parental: 3.3 and 3.64 mg/kg bw/day (male and female, respectively), based on 
effects in liver and thyroid in male and female rats, and seminal vesicle in males. 
NOAEL reproductive toxicity: 27.3 and 30.3 mg/kg bw/day (male and female, respectively), 
based on increased numbers of stillborn pups. 
 
4.1.5 EFFECTS IN RABBIT TERATOGENICITY STUDY  
In the rabbit teratogenicity study the number of runts was increased at 400 mg/kg bw/day. 
Compared to controls, there was an increase in the number of foetuses and litters with visceral 
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variants and anomalies including short innominate arteries (variant) from 100 mg/kg bw/day 
which on a litter basis was slightly above the upper limit of the historical control data. This 
effect was also seen at 400 mg/kg bw/day; however a clear dose-response relationship could 
be masked by the high dam mortality at this dose level. Sub-clavian right artery (anomalies) 
was dose-dependently increased, and also above the upper limits of the historical control data 
at 400 mg/kg bw/day.  Other visceral anomalies were also reported to be outside the historical 
control data at 400 mg/kg bw/day, including convoluted and dilated ureters (seen from 100 
mg/kg bw/day, but only outside the historical control data at 400mg/kg bw/day) and dilated 
renal pelvis and enlarged kidney.  
Skeletal anomalies reported included extra sternebral ossification sites that were significantly 
and dose-dependently increased from 100 mg/kg bw/day, and outside the historical control 
data.  
The effects observed in the pups are considered treatment related, and should not be regarded 
as secondary effects related to maternal toxicity. 
 
NOAELS from the teratogenicity study: 
NOAEL maternal: 25 mg/kg bw/day based on reduced bodyweight gain, hair loss and reduced 
or no excreta and increased liver weight from 100 mg/kg bw/day. 
NOAEL development: 25 mg/kg bw/day based on reduced foetal weight, increase in the 
percentage of litters with short innominate arteries, and extra sternebral ossification sites. 
 
4.1.6 ESTABLISHMENT OF REFERENCE VALUES  
 
NOAEL values: 
VKM proposes a NOAEL of 2.0 mg/kg bw/day for setting of ADI based on the 2 year toxicity 
study in rat, and is of the opinion that the test substance-related increased incidences of 
multinucleated hepatocytes and hepatocellular hypertrophy, as well as increased incidence of 
thyroid follicular cell hypertrophy and colloid alteration, is considered relevant for humans.  
VKM proposes a NOAEL of 12.9 mg/kg bw/day for setting AOEL based on a 90-day feeding 
study in rats, and is of the opinion that the test substance -related increase in hepatic 
centrilobular hypertrophy and thyroid follicular cell hypertrophy, is considered relevant for 
humans.  
VKM proposes a NOAEL of 2.0 mg/kg bw/day for setting ARfD based on a developmental 
toxicity study in rats, and is of the opinion that the test substance-related reduced foetal 
weight is considered relevant for humans. 
 
ADI  
An ADI of 0.02 mg/kg bw/day is proposed for bixafen based on applying a 100-fold 
uncertainty factor to NOAEL of 2.0  mg /kg bw/day based on a 2 year feeding study in rats. 
The uncertainty factor accounts for interspecies extrapolation (10X) and intraspecies 
variability (10X).  
 
 
 
22 
 
 Norwegian Scientific Committee for Food Safety (VKM) 13-204 
 
AOEL 
An AOEL of 0.13 mg/kg bw/day is proposed for bixafen based on applying a 100-fold 
uncertainty factor to the NOAEL of 12.9 mg /kg bw/day determined in the 90-day feeding 
study in rats. The NOAEL is based on the induction of hepatic centrilobular hypertrophy. 
ARfD 
An ARfD of 0.2 mg/kg bw/day is proposed for bixafen,  based on applying a 100-fold 
uncertainty factor to the NOAEL of 20 mg/kg bw/day determined in a rat developmental 
toxicity study. The NOAEL is based on the observed reduced foetal weight. 
 
4.2 HEALTH RISK CHARACTERIZATION 
4.2.1 HEALTH RISK DUE TO HUMAN EXPOSURE 
VKM has based the risk characterization for operators on the summary from the Norwegian 
Food Safety Authority (section 5.5), and related this to the suggested AOEL value as 
indicated here in section 2.1. 
4.2.1.1 Operator, worker and bystander exposure 
Operator exposure: 
The AOEL for bixafen is highly exceeded without the use of personal protective equipment 
(PPE), but when gloves are used during mixing and loading the estimated exposure is below 
the AOEL.   
Re-entry and bystander exposure: 
Re-entry is not considered relevant for the intended use. Bystander exposure is calculated to 
be well below the AOEL. 
4.2.2 HEALTH RISK DUE TO RESIDUES IN PRODUCTS FOR CONSUMPTION 
Not included in the terms of reference. 
 
4.3 ENVIRONMENTAL FATE ASSESSMENT 
In the terms of reference it was stated that VKM should look at the fate and behaviour in the 
environment and the ecotoxicological effects and risks with regard to the properties of the 
active substance and the product. The Panel on plant protection products of the Norwegian 
Scientific Committee for Food Safety (VKM) has reviewed the actual documentation and 
points out the following inherent properties of the product, the active substances and possible 
metabolites:  
4.3.1 DEGRADATION AND ACCUMULATION  IN SOIL  
Aerobic degradation studies in laboratory show that less than 10 % of bixafen was eliminated 
over the study duration (120 days). Half-life from laboratory studies was not calculated as the 
half-life had to be extrapolated beyond the study duration, but estimated to be >1 year.  One 
metabolite, M44, was identified and detected at maximum 2.9 % of applied radioactive dose. 
This is the same metabolite as from fluxapyroxad (BAS 700F) (EFSA, 2012a).  
From field studies with bixafen in four locations in Europe, data from Sweden and Germany 
show especially slow dissipation.  The DT50 value from the field dissipation trial in Germany 
was >1000 days for most of the kinetic models before normalization. The geometric mean 
DT50 value for normalised field dissipation from the four locations was 249 days.  
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The long half-lives indicate a high potential for accumulation in soil, and after 6 years of 
repeated use of bixafen in the on-going study in Germany, a plateau concentration was still 
not reached (2005-2010). EFSA (2012b) concluded that data on persistence in soil was not 
sufficient. Model calculations by Norwegian Food Safety Authority with the Finnish PEC soil 
calculator using worst case un-normalised field DT50 showed that a plateau was not reached 
after 20 years of continuous use. The panel concludes that bixafen is likely to be persistent in 
Norwegian soils with an associated risk of accumulation after repeated use. 
    
4.3.2 MOBILITY IN SOIL AND LEACHING TO GROUNDWATER 
Sorption studies indicate very high sorption of bixafen in soil, and leaching to groundwater is 
not likely. No data on the mobility of M44 has been submitted, but the metabolite M44 has 
been shown to exhibit high to very high mobility in studies on the active substance 
fluxapyroxad. Results from the groundwater modelling with M44show that the metabolite 
will leach to groundwater at levels above 0.1 mg/l in all nine FOCUS scenarios and above 
0.75 µg/L in three of these scenarios (EFSA, 2012b). VKM concludes that the metabolite 
M44 has a potential for leaching to groundwater.  
 
4.3.3 SOIL CONCENTRATIONS 
The substance is applied maximum two times each year. Following the second application, 
initial concentrations in soil (PIECsoil) have been calculated at 0.125 mg/kg. Following 
multiple year use, a maximum PECsoil has been calculated at 0.90 mg/kg (Finnish PEC 
calculator; 20 year repeated application). VKM supports the use of the worst case non-
normalised DT50 value from the northern-European field studies as input to long-term 
accumulation assessment.  
 
4.3.4 SURFACE WATER AND SEDIMENT CONCENTRATIONS 
Concentration in surface water and sediments are calculated using FOCUS scenarios. The 
highest concentration in surface water with application rates relevant for Norway was 0.6 
µg/L and 5.0 µg/kg in sediments. Spray-drift is considered to be the major contributing factor, 
except for one scenario where runoff was more significant. None of the locations used in 
FOCUS scenarios are very steep (a few % slope, compared to >10 % in many areas in 
Norway). Steep slopes in combination with particle-sorbed pesticides typically give a high 
runoff contribution due to erosion.  
Similar to in soils, bixafen shows a very slow elimination from sediments. Accumulation in 
sediment cannot be excluded, with a maximum PEC estimated at 95.7 ug/kg after 20 years  
(United Kingdom, 2011). A default DT50 value of > 1000 days was used for calculation of 
PECsediment. The panel considers these maximum PEC values to be relevant for aquatic risk 
assessment.  
Assessment of criteria for classification of bixafen as a Persistent Organic Pollutant (POP) has 
been screened. Bixafen meets the criteria for persistence and adverse effects with toxicity to 
aquatic organisms. Bixafen also showed potential for bioaccumulation in a test with fish (BCF 
of 695), but the value was lower than the threshold value of 1000. Bixafen does not meet the 
criteria for potential for long range transport (United Kingdom, 2012).  
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4.4 ENVIRONMENTAL RISK CHARACTERIZATION 
The Panel’s risk characterization of the product’s ecotoxicological effects on terrestrial and 
aquatic organisms is based on the summary from the Norwegian Food Safety Authority 
presented in section 3.4.3-3.4.4 and exposure-, dose/response assessments and risk scale 
described in section 2.2. In additions documents from EFSA (2012a, 2012b) and Draft 
Assessment Reports (DAR) (United Kingdom, 2011 and 2012) has been used.  
 
4.4.1 EFFECTS AND RISKS TO TERRESTRIAL ORGANISMS 
Based on available information, there is minimal risk for toxic effects of bixafen to mammals, 
birds, bees, earthworms, plants and soil microorganisms with the proposed application 
regime. None of the trigger values for these organisms are exceeded.  
The panel concludes that there is minimal risk for toxic effects of bixafen to terrestrial 
organisms with the proposed application regime.  
 
4.4.2 EFFECTS AND RISK TO AQUATIC ORGANISMS  
Bixafen is very toxic to aquatic organisms. Trigger values for chronic toxicity to fish was 
exceeded for exposure calculations with FOCUS step 3 without mitigation measures. When a 
5 m spray drift bufferzone was established, the majority of the FOCUS scenarios indicated 
minimal risk to fish. However, the runoff scenario for stream still exceeded the relevant 
trigger for fish, suggesting that a 10 m buffer zone is necessary to achieve minimal risk.  
The Panel concludes that there is minimal risk for toxic effects of bixafen to aquatic 
organisms taking into account the suggested mitigation of a 10 m bufferzone.  
 
4.5 QUALITY OF THE SUBMITTED DOCUMENTATION 
VKM is of the opinion that the documentation submitted to VKM is adequate as a basis for an 
evaluation of the active substance, the metabolites, and for the technical material.  
 
5 Conclusion 
5.1 HEALTH 
VKM concluded that the liver effects reported in sub-chronic and chronic studies in rats, dogs 
and mice exposed to bixafen, as well as the effects on coagulating parameters, should be 
considered adverse and of relevance to humans. 
It is the opinion of VKM that the thyroid follicular cell tumours reported in female rats 
exposed to bixafen is not sufficient to suggest that bixafen has a tumour inducing potential.  
It is further the opinion of VKM that it cannot be excluded that the reduced pup weight during 
lactation in the two-generation study is mediated by bixafen via the milk, and that bixafen has 
a direct effect on the number of stillborn pups in the F1 and F2 generation.     
Finally, the pup developmental variants and anomalies reported in the teratogenicity study are 
considered treatment related, and not a secondary effects related to maternal toxicity. 
VKM proposes:  
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• NOAEL of 2.0 mg/kg bw/day based on a 2 year feeding study in rats. 
• ADI: 0.02 mg/kg bw/day 
• AOEL: 0.13 mg/kg bw/day 
• ARfD: 0.2 mg/kg bw/day   
Risk calculations show minimal risk if personal protective equipment is used. 
5.2 ENVIRONMENT 
Bixafen is shown to be persistent in soil. VKM considers the results from a field study on a 
German site and the Finnish PEC calculator to be relevant and concludes that repeated annual 
applications can cause accumulation in soil under Norwegian conditions. There is also a 
potential for groundwater contamination from leaching of the metabolite M44. 
VKM has concluded that the use of bixafen as an ingredient in Aviator Xpro EC with the 
proposed application regime in Norway will represent a minimal risk for toxic effects to 
terrestrial organisms.   
The toxicity of bixafen to aquatic organisms is high, and minimal risk of effects in surface 
waters can be achieved only if risk mitigation measures with bufferzones of 10 m are applied. 
 
6 Documentation 
The documentation submitted by the applicant in the process of application for registration of 
Aviator Xpro EC 225 has been compiled and evaluated by The Norwegian Food Safety 
Authority. (www.Mattilsynet.no) 
In addition, VKM has performed a combined literature search in PubMed, TOXNET and 
Embase using the name of the active substance (bixafen). The resulting references has been 
considered by VKM and used in the risk assessment when relevant. 
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